(NASDAQ: VTRS) Viatris's forecast annual revenue growth rate of 0.36% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 9.18%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.08%.
Viatris's revenue in 2024 is $15,426,900,000.On average, 2 Wall Street analysts forecast VTRS's revenue for 2024 to be $18,422,772,084,128, with the lowest VTRS revenue forecast at $18,421,928,910,033, and the highest VTRS revenue forecast at $18,423,615,258,224. On average, 2 Wall Street analysts forecast VTRS's revenue for 2025 to be $18,472,644,050,541, with the lowest VTRS revenue forecast at $18,391,764,653,648, and the highest VTRS revenue forecast at $18,553,523,447,433.
In 2026, VTRS is forecast to generate $18,519,190,823,336 in revenue, with the lowest revenue forecast at $18,354,831,253,114 and the highest revenue forecast at $18,683,550,393,557.